Nasopharyngeal carcinoma: alternative treatment options after disease progression. - Test2 - elhamkhani - TriplyDB

Nasopharyngeal carcinoma: alternative treatment options after disease progression.

Nasopharyngeal carcinoma: alternative treatment options after disease progression.

http://www.wikidata.org/entity/Q37705415

about

Concurrent alterations of RAGE, RECK, and MMP9 protein expression are relevant to Epstein-Barr virus infection, metastasis, and survival in nasopharyngeal carcinoma.Stressors alter intercellular communication and exosome profile of nasopharyngeal carcinoma cells.Mitochondrial DNA haplogroup confers genetic susceptibility to nasopharyngeal carcinoma in Chaoshanese from Guangdong, China.Conditioned media from cell lines: a complementary model to clinical specimens for the discovery of disease-specific biomarkers.Characterization of TRIP6-dependent nasopharyngeal cancer cell migration.A new naturally derived photosensitizer and its phototoxicity on head and neck cancer cells.T cell therapy for nasopharyngeal carcinoma.Zoledronic acid inhibits proliferation and impairs migration and invasion through downregulating VEGF and MMPs expression in human nasopharyngeal carcinoma cells.Methodological Approaches to Study Extracellular Vesicle miRNAs in Epstein⁻Barr Virus-Associated Cancers

P2860

Q33898573-FC7BD0A2-B93C-408B-9AE9-94135506D9CE Q36123966-4CF7CEA1-3B72-4FEE-89A0-60B31B3401E8 Q37539168-E5BD18FA-5E05-45C9-A44B-0069742AD91F Q37828118-BDAE9DF3-686E-4560-8E97-42C3B22E0E8E Q39168334-2D8380E7-AD54-4A2E-B1D8-1633C678DBAC Q39550109-12A456E7-8A7F-40DD-A572-B0C5C59654EE Q42766336-D6F43EC8-8068-4E3A-A988-7404D7351268 Q44240872-EDA0DD9C-0BE6-4784-9AEC-A659882C0DAB Q58722656-AC5514A8-13F6-4FF5-AB81-E2F6FA2C82B2

P2860

Nasopharyngeal carcinoma: alternative treatment options after disease progression.

http://www.wikidata.org/entity/Q37705415

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on March 2010

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Nasopharyngeal carcinoma: alternative treatment options after disease progression.

@en

Nasopharyngeal carcinoma: alternative treatment options after disease progression.

@nl

type

label

Nasopharyngeal carcinoma: alternative treatment options after disease progression.

@en

Nasopharyngeal carcinoma: alternative treatment options after disease progression.

@nl

prefLabel

Nasopharyngeal carcinoma: alternative treatment options after disease progression.

@en

Nasopharyngeal carcinoma: alternative treatment options after disease progression.

@nl

P1433

Q37705415-9526A64D-36F7-440C-BAAD-C14890FC1074

P1476

Q37705415-9239034A-4D3F-4C6E-AE30-2590F0119FEE

P2093

Q37705415-0FD33664-A428-4A93-B62F-DCA8EF971B80

Q37705415-1A0F785A-5716-4D75-AB43-EA51A3CB7681

Q37705415-4E4E344F-9EB0-440D-B19E-F7E77F318AD5

Q37705415-867A7E0A-3D10-4268-846F-07EC030B27D9

Q37705415-DDD9B017-81F8-48EA-AB82-4D486B345401

P2860

Q37705415-023E8C0F-6E34-4386-9707-EA4B52DB5968

Q37705415-099EFCBA-0752-41FF-BC05-C20536E8706C

Q37705415-106157E8-3399-4280-93C5-0DF3B9DD3847

Q37705415-10756E65-02E1-4D8D-9F1A-945A1FDFADD0

Q37705415-11A521F6-E168-41AD-B79C-44D925E3B9B4

Q37705415-19384565-EC88-476D-A0CC-EBB38F44E3AF

Q37705415-19C12645-29F1-4F52-9622-30145CFDF60A

Q37705415-1A3D9155-AF34-4A63-82DE-D4C93A602780

Q37705415-1ADBCCB6-2E47-483B-9B8B-80E951860102

Q37705415-1B11A21D-2496-4A07-91C7-A112AF63BA84

P304

Q37705415-F45B2B48-B21F-40C7-A22D-8890F8762F4D

P31

Q37705415-2A0B69A1-2728-45C6-886C-02ADD680CB46

P356

Q37705415-02C37EA0-3EF7-4C8A-A240-7CFA5C84F8AF

P433

Q37705415-06EE8D67-1D92-4737-90DF-78B8264665C0

P478

Q37705415-DF716E71-90D0-40A2-BA4D-9D28A54E6E52

P577

Q37705415-82A3528A-F4CD-4A93-8228-D5E18294F260

P5875

Q37705415-80462447-EB0F-4D9A-A662-E5723DEBDCF7

P698

Q37705415-81FDC418-165B-4013-9A8A-E7458877A834

P356

P1433

Expert Review of Anticancer Therapy

P1476

Nasopharyngeal carcinoma: alternative treatment options after disease progression.

@en

P2093

Aurelio B Castrellon

http://www.w3.org/2001/XMLSchema#string

Belisario A Arango

http://www.w3.org/2001/XMLSchema#string

Cesar A Perez

http://www.w3.org/2001/XMLSchema#string

Edgardo S Santos

http://www.w3.org/2001/XMLSchema#string

Luis E Raez

http://www.w3.org/2001/XMLSchema#string

P2860

Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer

Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck

A phase II study of combination paclitaxel and carboplatin in advanced nasopharyngeal carcinoma.

Phase II trial combining mitomycin with 5-fluorouracil, epirubicin, and cisplatin in recurrent and metastatic undifferentiated carcinoma of nasopharyngeal type.

A phase II study of ifosfamide, 5-fluorouracil and leucovorin in patients with recurrent nasopharyngeal carcinoma previously treated with platinum chemotherapy.

Combination gemcitabine and cisplatin chemotherapy for metastatic or recurrent nasopharyngeal carcinoma: report of a phase II study.

Phase II study of gemcitabine plus vinorelbine in the treatment of cisplatin-resistant nasopharyngeal carcinoma.

Induction chemotherapy with a new regimen alternating cisplatin, fluorouracil with mitomycin, hydroxyurea and bleomycin in carcinomas of nasopharynx or other sites of the head and neck region.

Triplet combination of gemcitabine, paclitaxel, and carboplatin followed by maintenance 5-fluorouracil and folinic acid in patients with metastatic nasopharyngeal carcinoma.

Endoscopic nasopharyngectomy with potassium-titanyl-phosphate (KTP) laser for early locally recurrent nasopharyngeal carcinoma.

P304

377-386

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1586/ERA.10.1

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

10

http://www.w3.org/2001/XMLSchema#string

P577

2010-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

41847762

http://www.w3.org/2001/XMLSchema#string

P698

20214519

http://www.w3.org/2001/XMLSchema#string